Medicon Valley Biomedical Newsletter

7TM Pharma A/S has initiated a phase I/II clinical trial for TM30339, selected from the company's novel development program for treatment of obesity. TM30339 is the second clinical development can...

Bavarian Nordic A/S has received notification from the U.S. Department of Health and Human Services, HHS, that it intends to procure 20 million doses of the company's third-generation IMVAMUNE smallpo...

BioGaia AB has signed an agreement with Everidis Health Sciences LLC giving Everidis the rights to sell BioGaia Probiotic drops, chewable tablets and straws in the USA. The products will be sold under...

BioGaia AB has signed an agreement with Semper AB which gives Semper the rights to add Lactobacillus reuteri in gruel products in the Nordic markets. BioGaia's patented probiotic, Lactobacillus reuter...

A research team from Copenhagen University led by Henrik Clausen has identified enzymes that can eliminate antigens from the blood. Antigens in the red blood cells in blood type A and B can cause life...

Research scientists from a number of Danish companies and universities have joined in an innovation consortium to learn more about how drugs and dietary supplements influence the body's immune sys...

Egalet A/S has announced that it has successfully raised EUR 14,4 million in a Series B financing led by internationally renowned Danish investor, Vækstfonden Life Science Ventures. All existing inves...

Genmab A/S has announced that they will initiate research cooperation with the Danish Head and Neck Cancer Group, DAHANCA. Under the cooperation Genmab will supply the fully human antibody HuMax-EGFr,...

Genmab A/S has announced that a Phase II study of HuMax-EGFr in combination with chemo-radiation to treat non small cell lung cancer, NSCLC, has been initiated. The study will include a maximum of 270...

LIDDS AB, Local Implant Drug Delivery System, has announced the successful completion of a EUR 4,4 million financing round for the next phase of development of its drug delivery technology and lead pr...

Create Health at Lund University has received a grant of EUR 2,7 million from the Knut and Alice Wallenbergs foundation. The grant will be used for investments in new technologies which will extend Cr...

MediCult A/S has entered into a non-exclusive agreement with Cryo Bio System, a division of IMV Technologies to distribute the High Security Vitrification device together with the MediCult vitrificati...

Osteologix Inc. has announced that it has completed enrolment in its phase II clinical trial of NB S101, the company's investigational drug for osteoporosis. Osteologix has enrolled 289 postmenopa...

Pharmexa A/S and Norwegian Affitech AS have entered into a license agreement to promote a single chain bi-specific antibody technology to third parties for further product development, as well as to u...

Pharmexa A/S has developed the immunotherapeutic drug GV1001, which has now entered phase III trial testing for treatment of pancreatic cancer. Pharmexa is co-financing the trial together with pharmac...

Probi AB's partner Institut Rosell has signed agreements for the launch of dietary supplements containing Probi's probiotic, the bacteria Lp299v, in Greece, the Czech Republic and Slovakia. Wi...

Symphogen A/S and Biovitrum AB have announced the initiation of a Phase I clinical trial to test the safety, pharmacokinetics and pharmacodynamics of Sym001, Anti-RhD, in healthy volunteers. Up to 39 ...